Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06399406
Other study ID # 809712
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 15, 2024
Est. completion date April 30, 2026

Study information

Verified date May 2024
Source University of California, San Diego
Contact Jyoti Mishra, PhD
Phone 8582322855
Email braine@ucsd.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of ~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.


Description:

This study aims to develop a novel multimodal treatment for treatment resistant depression (TRD), which combines intermittent theta burst stimulation (iTBS), a type of FDA-approved rTMS protocol, with digital mindfulness training. We propose that this multimodal treatment will suppress posterior Default Mode Network (pDMN) brain activity as measured with electroencephalography (primary outcome and neural target), as well as enhance cognition and alleviate depression symptoms in patients with TRD. The study will determine the optimal dose required for neural target engagement by the multimodal iTBS + digital mindfulness training relative to an active control training combined with iTBS.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date April 30, 2026
Est. primary completion date April 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Diagnosis of major depressive episode (MDE, in accordance with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), in the context of unipolar major depressive disorder. - At least one failed antidepressant medication trial at level 3 in the Antidepressant Treatment History Form: Short Form (ATHF-SF) classification. - Montgomery-Åsberg Depression Rating Scale (MADRS) Score of >19 (moderate - severe depression). - No increase or initiation of new antidepressant therapy in the four weeks prior to screening. - Demonstrated capacity to give informed consent. Exclusion Criteria: - Inability to provide informed consent. - Medically unstable patients. - Concomitant neurological disorder or a history of a seizure disorder. - Exhibiting current suicidal behavior rating on the Columbia Suicide Severity Rating Scale (C-SSRS) - Patients who are pregnant or breastfeeding. - Any psychotic disorder or current active psychotic symptoms. - Patients who have intracranial implants, other medical device or condition deemed unsafe for TMS. - Contraindication to MRI scanning.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Medi-TBS
The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.

Locations

Country Name City State
United States University of California San Diego La Jolla California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Working Memory Span-weighted efficiency will be measured on a standard Delayed Match to Sample Task 4 weeks
Other Change in Mindful Attention Awareness Scale (MAAS) The MAAS will be used to evaluate change in subjective state mindfulness. Scale range: 6-84, higher score is greater mindfulness 4 weeks
Other Change in Rumination Reflection Questionnaire (RRQ) The RRQ will be used to evaluate change in subjective rumination. Scale range: 22-88, higher score is greater rumination 4 weeks
Other Change in Patient Health Questionnaire 9 item scale (PHQ9) The PHQ9 scale will be used as an additional measure to evaluate change in depressive symptom response. Score range: 0-27, higehr score is greater depression 8 weeks
Other Change in Generalized Anxiety Disorder 7 item scale (GAD7) The GAD7 scale will be used as a measure to evaluate change in anxiety symptom response.
Score range: 0-21, higher score is greater anxiety
8 weeks
Primary Change in EEG source localized pDMN alpha activity EEG alpha band (8-12 Hz) activity source-localized to the posterior Default Mode Network (pDMN) brain region extracted on distracted trials of the Breath Attention Assessment of Mindfulness task serves as the primary neural target. 4 weeks
Secondary Change in Selective Attention Processing speed of response to target stimuli on a standard continuous performance task that measures the ability to selectively attend and promptly respond to a goal-relevant target stimulus serves as the secondary cognitive target. 4 weeks
Secondary Change in Flanker Inhibition Efficiency of inhibiting visuo-spatially flanking distractors to target stimuli in the Flanker task serves as the secondary cognitive target. 4 weeks
Secondary Change in Montgomery Åsberg Depression Rating Scale Scores (MADRS) The MADRS will be used to evaluate % depressive symptom response defined as 50% change in the MADRS score from baseline as well as remission defined as MADRS score <7 at post-intervention. Scale range: 0-54, higher score is worse depression. 8 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A